期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 9, 期 8, 页码 1099-1106出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712590903055011
关键词
hematopoietic stem cells; natalizumab; VLA-4
The humanized monoclonal very late antigen 4 (VLA-4) antibody natalizumab is FDA approved for the treatment of patients with multiple sclerosis and Crohn's disease. In this review we focus on its role in the context of hematopoietic stem cell transplantation and stem cell diseases. The use of natalizumab alone or in combination with either cytotoxic drugs or other antibodies might be a new modality for stem cell mobilization and a therapeutic option for patients with hematologic malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据